RU2607033C2 - Пептиды nd2 и способы лечения неврологического заболевания - Google Patents

Пептиды nd2 и способы лечения неврологического заболевания Download PDF

Info

Publication number
RU2607033C2
RU2607033C2 RU2013119830A RU2013119830A RU2607033C2 RU 2607033 C2 RU2607033 C2 RU 2607033C2 RU 2013119830 A RU2013119830 A RU 2013119830A RU 2013119830 A RU2013119830 A RU 2013119830A RU 2607033 C2 RU2607033 C2 RU 2607033C2
Authority
RU
Russia
Prior art keywords
peptide
src
pain
tat
seq
Prior art date
Application number
RU2013119830A
Other languages
English (en)
Russian (ru)
Other versions
RU2013119830A (ru
Inventor
Майкл ТИМИАНСКИ
Жунвэнь ЛИ
Джонатан Дэвид ГАРМАН
Original Assignee
Ноно Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ноно Инк. filed Critical Ноно Инк.
Publication of RU2013119830A publication Critical patent/RU2013119830A/ru
Application granted granted Critical
Publication of RU2607033C2 publication Critical patent/RU2607033C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/05—Oxidoreductases acting on NADH or NADPH (1.6) with a quinone or similar compound as acceptor (1.6.5)
    • C12Y106/05003—NADH dehydrogenase (ubiquinone) (1.6.5.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2013119830A 2010-09-28 2011-09-28 Пептиды nd2 и способы лечения неврологического заболевания RU2607033C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38743910P 2010-09-28 2010-09-28
US61/387,439 2010-09-28
PCT/US2011/053764 WO2012050921A2 (en) 2010-09-28 2011-09-28 Nd2 peptides and methods of treating neurological disease

Publications (2)

Publication Number Publication Date
RU2013119830A RU2013119830A (ru) 2014-11-10
RU2607033C2 true RU2607033C2 (ru) 2017-01-10

Family

ID=45938878

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013119830A RU2607033C2 (ru) 2010-09-28 2011-09-28 Пептиды nd2 и способы лечения неврологического заболевания

Country Status (15)

Country Link
US (1) US9073976B2 (enExample)
EP (1) EP2621945B1 (enExample)
JP (1) JP6073230B2 (enExample)
KR (1) KR101893473B1 (enExample)
CN (1) CN103282379B (enExample)
AU (1) AU2011314074B2 (enExample)
BR (1) BR112013007557A2 (enExample)
CA (1) CA2812948C (enExample)
DK (1) DK2621945T3 (enExample)
IL (1) IL225464B (enExample)
MX (1) MX343366B (enExample)
RU (1) RU2607033C2 (enExample)
SG (1) SG189104A1 (enExample)
UA (1) UA114592C2 (enExample)
WO (1) WO2012050921A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123820C2 (uk) * 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CN109072242A (zh) * 2016-02-23 2018-12-21 科罗拉多州立大学董事会法人团体 用于治疗神经损伤的基于肽的方法
US11229675B2 (en) * 2016-04-27 2022-01-25 Biocells (Beijing) Biotech Co., Ltd. Therapeutic peptides for excitatory neurotoxicity-related injuries
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN112679595B (zh) * 2020-04-10 2022-11-01 南京市儿童医院 脑源肽或融合肽在新生儿缺氧缺血性脑损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
WO2008025130A1 (en) * 2006-08-29 2008-03-06 The Hospital For Sick Children Method for ameliorating pain by modification of nmda receptors through inhibition of src
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281129T3 (es) * 1997-08-12 2007-09-16 Bristol-Myers Squibb Company Canales de potasio kcnq y procedimientos para su modulacion.
CA2368229A1 (en) * 1999-03-19 2000-09-28 Craig A. Rosen 50 human secreted proteins
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
EP1551424B1 (en) * 2002-09-04 2015-07-01 Arrowhead Research Corporation Treatment of chronic neuropathic pain by admistration of dsrna
EP1912680B1 (en) * 2005-06-15 2014-11-26 The Ohio State University Research Foundation Her-2 peptides
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005106871A (ru) * 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
WO2008025130A1 (en) * 2006-08-29 2008-03-06 The Hospital For Sick Children Method for ameliorating pain by modification of nmda receptors through inhibition of src

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt последовательность Q7GHE2, размещена 05.07.2004 *
GINGRICH ET AL., Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2, PNAS, 2004, v.101, n.16, p.6237 - 6242. *
LIU ET AL, Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex, NATURE MEDICINE, 2008, v.14, n.12, p.1325 - 1332. *
LIU ET AL, Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex, NATURE MEDICINE, 2008, v.14, n.12, p.1325 - 1332. GINGRICH ET AL., Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2, PNAS, 2004, v.101, n.16, p.6237 - 6242. DATABASE UniProt последовательность Q7GHE2, размещена 05.07.2004. *

Also Published As

Publication number Publication date
WO2012050921A2 (en) 2012-04-19
CA2812948A1 (en) 2012-04-19
MX2013003330A (es) 2013-09-26
JP2014505655A (ja) 2014-03-06
IL225464A0 (en) 2013-06-27
CN103282379A (zh) 2013-09-04
MX343366B (es) 2016-11-01
UA114592C2 (uk) 2017-07-10
SG189104A1 (en) 2013-05-31
DK2621945T3 (en) 2018-05-22
RU2013119830A (ru) 2014-11-10
US20140274906A1 (en) 2014-09-18
US9073976B2 (en) 2015-07-07
AU2011314074A1 (en) 2013-05-09
AU2011314074B2 (en) 2015-11-12
CA2812948C (en) 2019-01-22
CN103282379B (zh) 2016-01-06
KR101893473B1 (ko) 2018-08-30
EP2621945B1 (en) 2018-04-11
KR20140048070A (ko) 2014-04-23
IL225464B (en) 2018-03-29
BR112013007557A2 (pt) 2021-05-11
JP6073230B2 (ja) 2017-02-01
EP2621945A2 (en) 2013-08-07
WO2012050921A3 (en) 2012-07-05
EP2621945A4 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
JP6005357B2 (ja) てんかんの治療
JP6775478B2 (ja) 内在化ペプチド連結薬剤と抗炎症剤との共投与
JP2005523326A (ja) プロテインキナーゼｃのペプチドインヒビター
HUE027216T2 (en) Co-administration of an agent associated with a tat internalizing peptide with an anti-inflammatory agent
AU2008223469A1 (en) Treating stroke and other diseases without inhibiting N-type calcium channels
US9073976B2 (en) ND2 peptides and methods of treating neurological disease
AU2017306558A1 (en) Reelin compositions for treatment of neurological disorders
KR102919967B1 (ko) 신경 가소성을 유도하기 위한 방법 및 조성물
HK1187931B (en) Nd2 peptides and methods of treating neurological disease
HK1187931A (en) Nd2 peptides and methods of treating neurological disease

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant